PharmaNet, a Princeton, N.J., clinical drug development company once under U.S. Senate investigation for its treatment of human test subjects, now faces an avalanche of shareholder litigation.
A putative class-action suit in federal court in Newark alleges the company and its top executives made false and misleading statements to investors, engaged in improper business practices and tried to cover them up.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]